<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13305">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933710</url>
  </required_header>
  <id_info>
    <org_study_id>JEC18</org_study_id>
    <secondary_id>U1111-1174-4824</secondary_id>
    <nct_id>NCT02933710</nct_id>
  </id_info>
  <brief_title>Postmarketing Surveillance Study for IMOJEV® in Republic of Korea</brief_title>
  <official_title>Postmarketing Surveillance Study for a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Republic of Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to perform the re-examination of IMOJEV® in routine clinical
      settings in accordance with the Ministry of Food and Drug Safety regulation.

      Primary objective:

        -  To describe the safety profile of the first dose of IMOJEV® administered under routine
           health care visit as primary vaccination or as booster.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects aged 12 months of age and older and who are given study vaccine during routine
      health-care visits will be enrolled in the study. They will also receive one dose of booster
      12 to 24 months after the primary dose.

      No study vaccine will be supplied or administered as part of this study, subjects will be
      monitored following routine vaccine administration in clinical settings.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants reporting solicited injection-site reactions, solicited systemic reactions, unsolicited adverse events, and serious adverse events occurring during the trial</measure>
    <time_frame>Day 0 up to Day 48 post-vaccination</time_frame>
    <description>Solicited injection-site reactions: Tenderness/Pain, Erythema, and Swelling. Solicited systemic reactions: infants and toddlers (12 to 23 months) Fever (temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite and Irritability; Subjects aged 2 to 55 years, Fever (Temperature), Headache, Malaise, and Myalgia</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">632</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>IMOJEV Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 12 months and older will receive a primary and a booster dose of IMOJEV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>IMOJEV Vaccine Group</arm_group_label>
    <other_name>IMOJEV®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent form signed by the subject (for subjects 19 years old and above) or
             the parent(s) or other legal representative (for subjects under 19 years of age)

          -  Receipt of the first dose of IMOJEV® (on the day of inclusion) according to approved
             local insert paper.

        Exclusion Criteria:

          -  Participation at the time of study enrollment (or in the 4 weeks preceding the study
             vaccination) or planned participation during the present study period in another
             clinical study investigating a vaccine, drug, medical device, or a medical procedure.

          -  Subjects who already participated in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Public Registry Sanofi Pasteur</last_name>
    <email>RegistryContactUs@sanofipasteur.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Jeju-si</city>
        <state>Jeju Self-Governing Province</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 12, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese encephalitis</keyword>
  <keyword>IMOJEV®</keyword>
  <keyword>Japanese encephalitis chimeric virus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: www.Clinicalstudydatarequest.com/Sanofi&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
